Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (terbuka di window baru)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Sumber‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Index‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (terbuka di window baru)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (terbuka di window baru)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Sumber‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Index‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (terbuka di window baru)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (terbuka di window baru)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Sumber‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Index‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (terbuka di window baru)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (terbuka di window baru)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Sumber‎: Blood 2003;102(4):1529-30.

Index‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (terbuka di window baru)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (terbuka di window baru)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Sumber‎: Transfusion 2007;47(10):1830-6.

Index‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (terbuka di window baru)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (terbuka di window baru)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Sumber‎: Iran J Blood Cancer 2009;1(4):147-50.

Index‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (terbuka di window baru)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (terbuka di window baru)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Sumber‎: Int J Hematol 2012;95(1):51-6.

Index‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (terbuka di window baru)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (terbuka di window baru)

Perrine SP.

Sumber‎: Pediatr Ann 2008;37(5):339-46.

Index‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (terbuka di window baru)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (terbuka di window baru)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Sumber‎: Sci Rep. 2022;12(1):2752.

Index‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (terbuka di window baru)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (terbuka di window baru)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Sumber‎: Haematologica 2004;89(10):1172-8.

Index‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (terbuka di window baru)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (terbuka di window baru)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Sumber‎: Arch Iran Med 2009;12(3):295-7.

Index‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (terbuka di window baru)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (terbuka di window baru)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Sumber‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Index‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (terbuka di window baru)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (terbuka di window baru)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Sumber‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Index‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (terbuka di window baru)

Fetal globin gene inducers: novel agents and new potential. (terbuka di window baru)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Sumber‎: Ann N Y Acad Sci 2010;1202:158-64.

Index‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (terbuka di window baru)